These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062 [TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid: a review of its use in the treatment of osteoporosis. Deeks ED; Perry CM Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264 [TBL] [Abstract][Full Text] [Related]
6. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Hadji P; Gamerdinger D; Spieler W; Kann PH; Loeffler H; Articus K; Möricke R; Ziller V Osteoporos Int; 2012 Feb; 23(2):625-33. PubMed ID: 21442459 [TBL] [Abstract][Full Text] [Related]
7. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. Reid IR; Brown JP; Burckhardt P; Horowitz Z; Richardson P; Trechsel U; Widmer A; Devogelaer JP; Kaufman JM; Jaeger P; Body JJ; Brandi ML; Broell J; Di Micco R; Genazzani AR; Felsenberg D; Happ J; Hooper MJ; Ittner J; Leb G; Mallmin H; Murray T; Ortolani S; Rubinacci A; Saaf M; Samsioe G; Verbruggen L; Meunier PJ N Engl J Med; 2002 Feb; 346(9):653-61. PubMed ID: 11870242 [TBL] [Abstract][Full Text] [Related]
8. Yearly zoledronic acid in postmenopausal osteoporosis. de Nijs RN; Westgeest AA N Engl J Med; 2007 Aug; 357(7):711; author reply 714-5. PubMed ID: 17699824 [No Abstract] [Full Text] [Related]
9. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. McClung M; Miller P; Recknor C; Mesenbrink P; Bucci-Rechtweg C; Benhamou CL Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099 [TBL] [Abstract][Full Text] [Related]
10. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project]. Dalle Carbonare L; Bertoldo F; Lo Cascio V Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189 [TBL] [Abstract][Full Text] [Related]
11. Yearly zoledronic acid in postmenopausal osteoporosis. Chang JT N Engl J Med; 2007 Aug; 357(7):713-4; author reply 714-5. PubMed ID: 17703528 [No Abstract] [Full Text] [Related]
12. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Matsumoto T; Hagino H; Shiraki M; Fukunaga M; Nakano T; Takaoka K; Morii H; Ohashi Y; Nakamura T Osteoporos Int; 2009 Aug; 20(8):1429-37. PubMed ID: 19101754 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. Orwoll ES; Miller PD; Adachi JD; Brown J; Adler RA; Kendler D; Bucci-Rechtweg C; Readie A; Mesenbrink P; Weinstein RS J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357 [TBL] [Abstract][Full Text] [Related]
14. Effect of zoledronic acid therapy on postmenopausal osteoporosis between the Uighur and Han population in Xinjiang: An open-label, long-term safety and efficacy study. Xu W; Xiang C; Wang H; Yuan H; Zhao X; Xiao X J Clin Pharm Ther; 2018 Jun; 43(3):336-341. PubMed ID: 29114907 [TBL] [Abstract][Full Text] [Related]
16. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density. Bachmann G; Kriegman A; Gonçalves J; Kianifard F; Warren M; Simon JA Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066 [TBL] [Abstract][Full Text] [Related]
17. Annual zoledronic acid for osteoporosis. BMJ Group Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701 [TBL] [Abstract][Full Text] [Related]
18. Yearly zoledronic acid in postmenopausal osteoporosis. Karam R; Camm J; McClung M N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529 [No Abstract] [Full Text] [Related]
19. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Bianchi G; Czerwinski E; Kenwright A; Burdeska A; Recker RR; Felsenberg D Osteoporos Int; 2012 Jun; 23(6):1769-78. PubMed ID: 21975558 [TBL] [Abstract][Full Text] [Related]
20. A once-yearly IV bisphosphonate for osteoporosis. Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523 [No Abstract] [Full Text] [Related] [Next] [New Search]